Get the Stockscreener App
23.25
5.87%
1.29
After Hours:
22.91
-0.34
-1.46%
Zai Lab Limited Adr stock is traded at $23.25, with a volume of 1.40M.
It is up +5.87% in the last 24 hours and up +26.57% over the past month.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
See More
Previous Close:
$21.96
Open:
$22.46
24h Volume:
1.40M
Relative Volume:
1.94
Market Cap:
$2.62B
Revenue:
$461.26M
Net Income/Loss:
$-175.95M
P/E Ratio:
-14.47
EPS:
-1.607
Net Cash Flow:
$-164.65M
1W Performance:
+8.70%
1M Performance:
+26.57%
6M Performance:
-20.89%
1Y Performance:
-23.47%
1-Day Range:
$22.43
$23.28
1-Week Range:
$20.37
$23.28
52-Week Range:
$15.96
$44.34
Zai Lab Limited Adr Stock (ZLAB) Company Profile
Name
Zai Lab Limited Adr
Sector
Industry
Phone
862161632588
Address
899 HALEI ROAD, SHANGHAI
Compare ZLAB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZLAB
Zai Lab Limited Adr
|
23.25 | 2.47B | 461.26M | -175.95M | -164.65M | -1.607 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Zai Lab Limited Adr Stock (ZLAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-25-25 | Resumed | Jefferies | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Mar-03-25 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-14-23 | Initiated | Morgan Stanley | Overweight |
| Aug-10-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-21-22 | Initiated | Macquarie | Outperform |
| Oct-12-21 | Initiated | Bernstein | Mkt Perform |
| Apr-28-20 | Initiated | Goldman | Buy |
| Apr-15-20 | Initiated | Guggenheim | Buy |
| Jul-12-19 | Initiated | BofA/Merrill | Buy |
| Jul-05-19 | Initiated | Macquarie | Outperform |
| Jan-29-19 | Initiated | Credit Suisse | Outperform |
| Nov-21-18 | Initiated | Jefferies | Buy |
| Jun-21-18 | Resumed | Leerink Partners | Outperform |
| Feb-14-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Initiated | JP Morgan | Neutral |
| Oct-16-17 | Initiated | Leerink Partners | Outperform |
View All
Zai Lab Limited Adr Stock (ZLAB) Latest News
Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas - GlobeNewswire Inc.
Assessing Zai Lab (NasdaqGM:ZLAB) Valuation After New Lung Cancer Trial Progress And Amgen Collaboration - Sahm
Zai Lab (ZLAB) officer auto-sells ADSs to cover RSU tax obligations - Stock Titan
Zai Lab (NASDAQ: ZLAB) CLO auto-sells 1,224 ADSs to cover RSU tax - Stock Titan
Zai Lab (ZLAB) CEO records small ADS sale to cover tax on RSUs - Stock Titan
Zai Lab (NASDAQ: ZLAB) CFO sells 853 ADSs in tax-related RSU vesting - Stock Titan
Tax-driven Zai Lab (ZLAB) ADS sale reported for company executive - Stock Titan
Zai Lab Ltd (ADR) stock: What investors need to know now - AD HOC NEWS
Zai Lab (NASDAQ: ZLAB) reports 5.74M ADS (57.4M ordinary shares) - Stock Titan
ZLAB (NASDAQ: ZLAB) insider files Form 144 showing 11,580 ADS sales - Stock Titan
[144] Zai Lab Ltd SEC Filing - Stock Titan
ZLAB (NASDAQ: ZLAB) Form 144 shows Rafael Amado sold ADS in Mar–Apr 2026 - Stock Titan
ZLAB (NASDAQ: ZLAB) notices proposed sale of 853 ADS; prior transfers listed - Stock Titan
Yajing Chen Sells 5,199 Shares of Zai Lab (NASDAQ:ZLAB) Stock - defenseworld.net
Zai Lab Limited And Amgen Inc. Collaborate To Advance DLL3 Targeted Combination Therapy In Small Cell Lung Cancer - BioPharma APAC
Zai Lab Limited (9688.HK) stock price, news, quote and history - Yahoo Finance Singapore
Zai Lab Limited (ZLAB) Stock Price, News, Quote & History - Yahoo! Finance Canada
Zai Lab Limited (ZLAB) stock price, news, quote and history - uk.finance.yahoo.com
Revenue per share of Zai Lab Ltd. Sponsored ADR – FWB:1ZL - TradingView
Zai Lab (NASDAQ:ZLAB) CFO Sells $106,007.61 in Stock - MarketBeat
Zai Lab (NASDAQ:ZLAB) Insider Sells $196,029.46 in Stock - MarketBeat
Zai Lab (NASDAQ:ZLAB) CEO Ying Du Sells 5,576 Shares - MarketBeat
Rafael Amado Sells 9,910 Shares of Zai Lab (NASDAQ:ZLAB) Stock - MarketBeat
Zai Lab (ZLAB) CEO nets shares after RSU vesting and tax sale - Stock Titan
Zai Lab (ZLAB) CFO exercises RSUs, automatic ADS sale for taxes - Stock Titan
Zai Lab (ZLAB) executive sells ADSs to cover tax after RSU vest - Stock Titan
Zai Lab Ltd (ADR) stock: China's biotech powerhouse eyes global gains - AD HOC NEWS
Zai Lab (ZLAB) CLO nets ADSs after RSU vesting and tax sale - Stock Titan
Rafael Amado reports ADS sales for ZLAB (NASDAQ: ZLAB) - Stock Titan
9,614 ADS tied to vesting listed by ZLAB (NASDAQ: ZLAB) with Fidelity broker - Stock Titan
Insider sells ZLAB (NASDAQ: ZLAB) ADS — Form 144 lists 4,194 shares - Stock Titan
Affiliate sale notice: ZLAB (NASDAQ: ZLAB) up to 5,199 ADS - Stock Titan
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy - BioSpace
Zai Lab (NASDAQ:ZLAB) Trading 9.5% HigherStill a Buy? - MarketBeat
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Hesai Group Sponsored ADR (NASDAQ:HSAI) Given Consensus Rating of “Buy” by Brokerages - Defense World
Hennes & Mauritz AB (OTCMKTS:HNNMY) Given Average Recommendation of “Hold” by Brokerages - Defense World
HBT Financial, Inc. (NASDAQ:HBT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
KeyCorp (NYSE:KEY) Price Target Cut to $24.00 by Analysts at Morgan Stanley - Defense World
Journey Medical Corporation (NASDAQ:DERM) Given Consensus Rating of “Hold” by Analysts - Defense World
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
BTC Capital Management Inc. Lowers Holdings in Verizon Communications Inc. $VZ - Defense World
Constellation Software Inc. (OTCMKTS:CNSWF) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
The Goldman Sachs Group Issues Positive Forecast for Bicara Therapeutics (NASDAQ:BCAX) Stock Price - Defense World
KANZHUN LIMITED Sponsored ADR (NASDAQ:BZ) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Precision Drilling Corporation (NYSE:PDS) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Sees Large Growth in Short Interest - MarketBeat
Zai Lab (NASDAQ:ZLAB) Shares Gap UpShould You Buy? - MarketBeat
《業績》再鼎醫藥(09688.HK)去年虧損收窄至1.76億美元 - AASTOCKS.com
Virtus Biotech ETF Holdings - Quiver Quantitative
Zai Lab Limited Adr Stock (ZLAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Zai Lab Limited Adr Stock (ZLAB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Edmondson Frazor Titus III | Chief Legal Officer |
Apr 06 '26 |
Sale |
20.45 |
1,224 |
25,028 |
23,366 |
| Du Ying | Chairperson & CEO |
Apr 06 '26 |
Sale |
20.45 |
2,653 |
54,249 |
1,122,626 |
| Chen Yajing | Chief Financial Officer |
Apr 06 '26 |
Sale |
20.45 |
853 |
17,442 |
31,705 |
| Amado Rafael | See Remarks |
Apr 06 '26 |
Sale |
20.45 |
2,739 |
56,007 |
57,022 |
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):